CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Hydroxychloroquine Pre-Exposure ProphylaxisWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug24 200 mg EIDD-2801 Wiki 0.71
drug1853 Placebo oral tablet Wiki 0.19
drug1822 Placebo Wiki 0.06

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D003141 Communicable Diseases NIH 0.09
D007239 Infection NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Protecting Health Care Workers From COVID-19 With Hydroxychloroquine Pre-exposure Prophylaxis: A Randomized, Placebo-controlled Trial

This is a double-blinded, randomized placebo-controlled trial to determine if pre-exposure prophylaxis (PrEP) with 400mg hydroxychloroquine (HCQ), taken orally once daily, for health care workers in the hospital reduces symptomatic and asymptomatic COVID-19 disease during the pandemic. 374 health care workers will be randomized at a 1:1 allocation between the intervention and placebo arms and followed for 90 days. The cumulative incidence of COVID-19 infection in the intervention group will be compared to the cumulative incidence of COVID-19 in the placebo group with relative (risk ratio and 95% CI) and absolute measures (risk difference and 95% CI).

NCT04352946 Prophylaxis COVID-19 Health Care Worker Hydroxychloroquine Drug: Hydroxychloroquine Pre-Exposure Prophylaxis Drug: Placebo oral tablet

Primary Outcomes

Description: Incidence of symptomatic and asymptomatic COVID-19 infection in health care workers

Measure: Cumulative Incidence of COVID-19 Infection

Time: 90 days

Secondary Outcomes

Description: Incidence of reported and grade of adverse events

Measure: Adverse events incidence

Time: 90 days

Description: Duration in days of symptomatic COVID-19 disease in HCW who had disease

Measure: Duration of symptomatic COVID-19 disease

Time: 90 days

Description: Duration in days of hospitalization attributed to COVID-19 disease in HCW who had disease

Measure: Days hospitalized attributed to COVID-19

Time: 90 days

Description: Number of HCW with respiratory failure attributable to COVID-19 disease requiring i) non-invasive ventilation or ii) intubation/mechanical ventilation in HCW who developed disease

Measure: Number or respiratory failure attributable to COVID-19 disease

Time: 90 days

Description: Cumulative Incidence of Mortality attributed to COVID-19 disease in HCW who developed disease

Measure: Mortality Incidence

Time: 90 days

Description: Number of days unable to work attributed to COVID-19 in HCW who developed disease

Measure: Days of work lost

Time: 90 days

Other Outcomes

Description: Proportion of participants with plasma able to neutralize SARS-CoV-2 virus (plaque reduction neutralization test) in vitro.

Measure: Proportion of HCW with plasma able to neutralize SARS-CoV-2 virus

Time: 90 days

Description: Number of participants with severity markers of host immune and endothelial activation measured at clinical presentation and their ability to predict severity and outcome.

Measure: Number of participants with severity markers of host immune and endothelial activation

Time: 90 days

No related HPO nodes (Using clinical trials)